Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spotlight on amisulpride in schizophrenia.

Monique P Curran1, Caroline M Perry

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|March 13, 2002
PubMed
Summary

Amisulpride effectively treats schizophrenia symptoms, including positive, negative, and affective symptoms, with a favorable tolerability profile. It is a recommended first-line treatment for acute and maintenance phases of schizophrenia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • Amisulpride is a substituted benzamide derivative and an atypical antipsychotic.
  • It selectively blocks presynaptic dopamine D(2)/D(3) autoreceptors at low doses, enhancing dopaminergic transmission.
  • At higher doses, it antagonizes postsynaptic D(2) and D(3) receptors, reducing dopaminergic transmission, particularly in the limbic system.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of amisulpride in patients with schizophrenia.
  • To compare amisulpride with other antipsychotics for positive, negative, and affective symptoms.
  • To determine optimal dosing strategies for different phases and symptom profiles of schizophrenia.

Main Methods:

  • Comparative trials involving patients with acute exacerbations of schizophrenia.
  • Randomized, double-blind trials in patients with predominantly negative symptoms.
  • Long-term treatment studies assessing quality of life and social functioning.
  • Assessment of neurological tolerability, including extrapyramidal symptoms.

Main Results:

  • Amisulpride (400-1200 mg/day) demonstrated efficacy comparable to haloperidol, flupenthixol, and risperidone for positive symptoms in acute schizophrenia.
  • Amisulpride showed superior efficacy over haloperidol and comparable efficacy to risperidone for negative symptoms.
  • Amisulpride (400-800 mg/day) was more effective than haloperidol, risperidone, and flupenthixol for affective symptoms.
  • Low-dose amisulpride (50-300 mg/day) was more effective than placebo for negative symptoms.
  • Long-term treatment improved quality of life and social functioning.
  • Neurological tolerability of amisulpride was superior to conventional antipsychotics and similar to risperidone.
  • Low-dose amisulpride exhibited an adverse event profile similar to placebo.

Conclusions:

  • Amisulpride is an effective first-line treatment option for schizophrenia in both acute and maintenance phases.
  • Dosages of 400-800 mg/day are recommended for acute exacerbations, with up to 1200 mg/day possible.
  • Lower dosages (50-300 mg/day) are suitable for managing negative symptoms.
  • Amisulpride offers advantages in treating negative and affective symptoms and has a better tolerability profile than conventional antipsychotics.

Related Experiment Videos